NEW YORK, NY -- (Marketwire) -- 06/08/12 -- A new report says there may be $24.8 billion of vaccines sold by 2020 that do not exist on the market today. What's Next in Vaccines?, published by Kalorama Information, details over thirty conditions, including malaria, diabetes, Alzheimer's, and allergies, for which there may be vaccines in coming years. The healthcare market research publisher made its finding based on interviews and a review of potential vaccine products in Phases I-III.
"Around the world, vaccine developers are investigating a large number of areas that would previously not have been considered treatable via inoculation," said Bruce Carlson, Publisher of Kalorama Information. "These range from conditions that cause discomfort but are not considered life threatening, such as allergies and Ross River fever, to diseases that significantly increase mortality, such as addiction and diabetes."
Using various novel technologies and mechanisms of action, emerging vaccines are being designed to address both infectious and non-infectious disease. They may be prophylactic, intended to prevent a disease before it starts, or therapeutic, designed to address a disease once it has become established; both types, by definition, seek to create an immune system response that will mitigate the targeted disease. Kalorama Information's forecast allows for the fact that a number of vaccine candidates will not turn into promising vaccines. It assumes that some vaccine candidates currently in Phase III will be commercialized in 2012, some candidates in Phase II will enter the market in 2014, some in Phase I will launch in 2016 and vaccines still in pre-clinical testing will see approval until in 2018. Kalorama says the "likely case" based on the sales of successful products will total $24.8 billion in 2020.
In recent years, Kalorama Information has detailed the growth in the vaccine market in its annual market research reports, and documented the increased interest in R&D departments at major pharmaceutical companies in developing vaccine products as one way to make up for revenues lost to off-patent pharmaceutical products. According to Kalorama Information, growth in the long-term will not come from the standard vaccine categories, such as influenza or pediatric combinations, but from diseases that are not currently thought of as vaccine treatable.
What's Next in Vaccines? (Malaria, Diabetes, Alzheimer's, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline) provides forecasted revenues for products in development out to 2020. The report assesses the severity of various diseases and the likelihood of available treatments for them. It also profiles companies marketing vaccines.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Please direct all media inquiries to:
Most Popular Stories
- SEO Traffic Lab Celebrate Wins at Digital Marketing Event 'Internet World 2013' in London
- Social Media Initiatives Should Follow Customers' Lead
- Apple CEO: Offshore Units Not a 'Tax Gimmick'
- U.S. Senate Accuses Apple of Large-scale Tax Avoidance
- UTEP Water Recycling Project Wins Venture Titles
- Marketo Makes a Mint in IPO: Stock Shoots Up More than 50 Percent
- Bieber Booed at Billboard Awards
- Crude Oil Up, Gasoline Down
- Austin Startup Compare Metrics Raises $3.5 Million for Expansion
- Why So Many Top 'Car Guys' Are Actually Women